Escitalopram

Generic Name: Escitalopram

Brand Names: Cipralex, Lexapro

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁FN_₂O

CAS Number: 128196-01-0

Unique Ingredient Identifier: 4O4S742ANY

Background: Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...

Indication: Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...

Associated Conditions: Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)

Associated Therapies: -

Clinical Trials

Prophylaxis of Psychiatric Symptoms During Anti-HCV Treatment

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: Escitalopram
Other: Placebo

First Posted Date: 2005-08-23

Last Posted Date: 2010-02-19

Lead Sponsor: Foundation for Liver Research

Target Recruit Count: 80

Registration Number: NCT00133276

Locations: 🇳🇱
Radboud University Hospital, Nijmegen, Netherlands
🇳🇱
Erasmus MC University Hospital, Rotterdam, Zuid-Holland, Netherlands
🇳🇱
AMC, Amsterdam, Netherlands

Treatment of Depression in the Elderly

Phase 4

Terminated

Conditions: Depression

First Posted Date: 2005-08-15

Last Posted Date: 2007-02-06

Lead Sponsor: Psychiatric Hospital, Hillerod

Target Recruit Count: 189

Registration Number: NCT00130455

Locations: 🇩🇰
Alex Koerner, Hilleroed, Denmark

Study of Escitalopram in the Treatment of Specific Phobia

Phase 2

Completed

Conditions: Phobic Disorders

First Posted Date: 2005-07-21

Last Posted Date: 2005-07-21

Lead Sponsor: Connor, Kathryn M., M.D.

Target Recruit Count: 12

Registration Number: NCT00121069

Locations: 🇺🇸
Dept of Psychiatry and Behvaioral Science, Duke Unviersity Medical Center, Durham, North Carolina, United States

Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD)

Phase 4

Completed

Conditions: Obsessive Compulsive Disorder

First Posted Date: 2005-06-30

Last Posted Date: 2007-04-24

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 30

Registration Number: NCT00116532

Locations: 🇺🇸
Massachusetts General Hospital - OCD Clinic, Charlestown, Massachusetts, United States

Escitalopram for the Treatment of Self-Injurious Skin Picking

Phase 4

Completed

Conditions: Impulse Control Disorders

First Posted Date: 2005-06-21

Last Posted Date: 2008-05-20

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 30

Registration Number: NCT00115011

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

SSRI Administration to Reduce Acute Stress Disorder Symptoms and Prevent Depression and PTSD in Physical Trauma Victims

Phase 3

Terminated

Conditions: Anxiety Disorder

First Posted Date: 2005-06-15

Last Posted Date: 2014-06-09

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 60

Registration Number: NCT00114374

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

First Posted Date: 2005-04-25

Last Posted Date: 2012-03-05

Lead Sponsor: Forest Laboratories

Target Recruit Count: 540

Registration Number: NCT00109044

Locations: 🇺🇸
Cunningham Clinical Research, LLC, Edwardsville, Illinois, United States
🇺🇸
Dominion Clinical Research, Midlothian, Virginia, United States
🇺🇸
Capital Clinical Research Associates, Rockville, Maryland, United States

and more 14 locations

Study of Escitalopram in Adult Patients With Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

First Posted Date: 2005-04-22

Last Posted Date: 2012-03-05

Lead Sponsor: Forest Laboratories

Target Recruit Count: 240

Registration Number: NCT00108979

Locations: 🇺🇸
Clinical Neuroscience Solutions, Memphis, Tennessee, United States
🇺🇸
Southwest Health, Ltd., Phoenix, Arizona, United States
🇺🇸
Summit Research Network, Seattle, Washington, United States

and more 4 locations

The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Escitalopram
Drug: Placebo

First Posted Date: 2005-04-06

Last Posted Date: 2012-04-06

Lead Sponsor: Forest Laboratories

Target Recruit Count: 312

Registration Number: NCT00107120

Locations: 🇺🇸
Psychiatric Associates, Overland, Kansas, United States
🇺🇸
Janus Center for Psychiatric Research, West Palm Beach, Florida, United States
🇺🇸
UCSD Outpatient Psychiatry Services, San Diego, California, United States

and more 25 locations

Drug Therapy for Generalized Anxiety Disorder Among the Elderly

Phase 4

Completed

Conditions: Anxiety Disorders
Generalized Anxiety Disorder

Interventions: Drug: Escitalopram

First Posted Date: 2005-03-16

Last Posted Date: 2017-05-08

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 177

Registration Number: NCT00105586

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy